fluorodeoxyglucose f18 has been researched along with Dyslipidemia in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Bax, WA; Cornel, JH; Hoogeveen, RM; Kaiser, Y; Knol, RJJ; Kroon, J; Opstal, TSJ; Stiekema, LCA; Stroes, ESG; Verberne, HJ | 1 |
| Anagnostopoulos, CD; Bilianou, H; Gardikioti, V; Georgakopoulos, A; Kafouris, P; Katsiki, N; Kolovou, G; Koutagiar, I; Liberopoulos, E; Miliou, A; Rallidis, L; Skoumas, I; Stamatelopoulos, K; Terentes-Printzios, D; Tousoulis, D; Vlachopoulos, C; Zacharis, E | 1 |
| Becher, T; Butler, SD; Cohen, P; Eljalby, M; Jiang, CS; Kramer, DJ; Mark, A; Marx, SJ; Palanisamy, S; Schöder, H; Vaughan, R; Wibmer, AG | 1 |
| Anagnostopoulos, CD; Antoniades, C; Antonopoulos, AS; Benetos, G; Drakopoulou, M; Georgakopoulos, A; Kafouris, P; Koutagiar, I; Miliou, A; Oikonomou, G; Petrocheilou, A; Pitsavos, C; Siores, I; Skoumas, I; Tousoulis, D; Toutouzas, K | 1 |
| Arguin, G; Beaudoin, JF; Bourzac, JF; Gendron, FP; Lecomte, R; Molle, CM; Paquette, M; Placet, M; Plourde, M; Rousseau, JA | 1 |
| Imeryuz, N; Ones, T; Ozguven, S; Turoglu, HT; Yilmaz, Y | 1 |
| Honnorat, J; Ritzenthaler, T; Verret, JM | 1 |
| Boer, C; Bosmans, JW; Diamant, M; Handoko, LM; Huisman, MC; Lammertsma, AA; Lubberink, M; Molthoff, CF; Ouwens, MD; van den Brom, CE; Vlasblom, R | 1 |
| Amano, T; Aoyama, T; Hayashi, M; Ishii, H; Matsubara, T; Murohara, T; Nishio, M; Takahashi, H; Tamaki, T; Tanaka, M; Toriyama, T; Yoshikawa, D | 1 |
2 trial(s) available for fluorodeoxyglucose f18 and Dyslipidemia
| Article | Year |
|---|---|
PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorodeoxyglucose F18; Humans; Inflammation Mediators; Male; Middle Aged; Netherlands; PCSK9 Inhibitors; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Time Factors; Treatment Outcome | 2019 |
Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Dose-Response Relationship, Drug; Dyslipidemias; Female; Femoral Artery; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
7 other study(ies) available for fluorodeoxyglucose f18 and Dyslipidemia
| Article | Year |
|---|---|
Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Aorta; Aortic Diseases; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Drug Administration Schedule; Dyslipidemias; Female; Fluorodeoxyglucose F18; Greece; Humans; Inflammation Mediators; Male; Middle Aged; PCSK9 Inhibitors; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Time Factors; Treatment Outcome | 2019 |
Brown adipose tissue is associated with cardiometabolic health.
Topics: Adipose Tissue, Brown; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
Visceral adipose tissue phenotype and hypoadiponectinemia are associated with aortic Fluorine-18 fluorodeoxyglucose uptake in patients with familial dyslipidemias.
Topics: Adiponectin; Adipose Tissue; Arteritis; Dyslipidemias; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Intra-Abdominal Fat; Metabolism, Inborn Errors; Phenotype; Positron Emission Tomography Computed Tomography | 2022 |
The loss of P2X7 receptor expression leads to increase intestinal glucose transit and hepatic steatosis.
Topics: Absorption, Physiological; Animals; Biological Transport; Cholesterol; Down-Regulation; Dyslipidemias; Enterocytes; Fatty Liver; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 2; Hyperglycemia; Insulin; Insulin Resistance; Intestines; Jejunum; Lipid Metabolism; Male; Mice; Receptors, Purinergic P2X7; Tissue Distribution; Triglycerides; Weight Gain | 2017 |
The role of active brown adipose tissue in human metabolism.
Topics: Adipose Tissue, Brown; Adult; Dyslipidemias; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Non-alcoholic Fatty Liver Disease; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
[Paraneoplastic chorea and behavioral disorders in a patient with anti-CV2/CRMP5 antibodies and two different tumors].
Topics: Aged, 80 and over; Autoantibodies; Chorea; Dyslipidemias; Electrodiagnosis; Fluorodeoxyglucose F18; Humans; Hydrolases; Magnetic Resonance Imaging; Male; Mediastinal Neoplasms; Mental Disorders; Microtubule-Associated Proteins; Myocardial Infarction; Nerve Tissue Proteins; Obsessive-Compulsive Disorder; Paraneoplastic Polyneuropathy; Positron-Emission Tomography; Radiopharmaceuticals; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2010 |
Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle.
Topics: Animals; Blood Glucose; Cardiomyopathies; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Echocardiography, Doppler; Fatty Acids; Fluorodeoxyglucose F18; Glucose Clamp Technique; Heart Ventricles; Hyperinsulinism; Insulin; Male; Phosphorylation; Positron-Emission Tomography; Proto-Oncogene Proteins c-akt; Radiopharmaceuticals; Rats; Rats, Zucker; Triglycerides; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Function, Left; Ventricular Function, Right | 2010 |